The first-of-its-kind targeted oral peptide therapy for moderate to severe plaque psoriasis has been chosen for the annual list, which recognizes innovations for their originality, ambition and impact.
Johnson & Johnson’s ICOTYDE® (icotrokinra) named to Time’s Best Inventions of 2026 list
calendar_today
October 15, 2026
domain
janssen